The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrate...
The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial
About this item
Full title
Author / Creator
Publisher
Public Library of Science
Journal title
Language
English
Formats
Publication information
Publisher
Public Library of Science
Subjects
More information
Scope and Contents
Contents
The role of surgical castration and rosuvastatin treatment on lipid profile and lipid metabolism related markers was evaluated for their prognostic significance in metastatic prostate cancer (mPC) patients. A total of 84 newly diagnosed castrated mPC patients treated with castration were recruited and divided into two groups: Group I served as cont...
Alternative Titles
Full title
The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_gale_infotracmisc_A729331024
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A729331024
Other Identifiers
ISSN
1932-6203
E-ISSN
1932-6203
DOI
10.1371/journal.pone.0278282
